

83825-DIAMINOPYRIDINE 3,4**1. IDENTIFICATION OF THE SUBSTANCE OR PREPARATION.****1.1 Identification of the substance or preparation.**

Name: Diaminopyridine 3,4

Bulk code: 83825

1.2 Synonyms.

3,4-Diaminopyridine, Amifampridine.

2. DESCRIPTION

Appearance: Crystalline powder.

Colour: White or slightly Brown.

3. COMPOSITION/INFORMATION ON COMPONENTS.Formula: $C_5H_7N_3$

CAS: 54-96-6

Molecular weight: 109.13 g/mol

4. PHYSICO-CHEMICAL DATA.

See detailed specifications on analysis certificate.

Solubility: The product is soluble in methanol, poorly soluble in water, practically insoluble in acetone.

5. PROPERTIES/USES.

ACTIVE PHARMACEUTICAL INGREDIENT.

Diaminopyridine-3,4 has similar actions and uses to those of aminopyridine-4, but is more potent in improving the release of acetylcholine from nerve endings.

It has been used to treat Lambert-Eaton syndrome and other myasthenic conditions. It has also been proven as a treatment for multiple sclerosis and botulism.

6. DOSAGE.

3,4-Diaminopyridine is given as phosphate, but doses are expressed as base.



GUINAMA. Laboratory distributor of raw materials for the pharmaceutical and cosmetic industries.

Type of document:

TECHNICAL DATA SHEET

Review date:

28.09.2022

Version:

2.0

83825-DIAMINOPYRIDINE 3,4

Orally:

- Lambert-Eaton myasthenic syndrome: Initial dose of 15 mg/day divided into 3 or 4 doses. The dose may be increased in 5 mg increments every 4 or 5 days up to a maximum of 60 mg daily, except in patients with renal or hepatic impairment.

7. REMARKS.

STORAGE:

Store at room temperature ($25 \pm 2^\circ\text{C}$), in a cool, dry place, away from sunlight, in a tightly closed container.

8. BIBLIOGRAPHY.

"Martindale. The Extra Pharmacopoeia". 30th Edition. Ed. The Pharmaceutical Press. London. (1993).